Recurrent Ovarian Clear Cell Adenocarcinoma (DBCOND0122845)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04092270	A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	Benzalkonium Doxorubicin Nedisertib Tetracycline	treatment	1	recruiting
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	Bevacizumab Pembrolizumab	treatment	2	recruiting
NCT04739800	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents	Cediranib Doxorubicin Durvalumab Olaparib Paclitaxel Tetracycline Topotecan	treatment	2	active_not_recruiting
NCT02839707	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Atezolizumab Bevacizumab Doxorubicin Tetracycline	treatment	2 / 3	active_not_recruiting
NCT06393751	Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer	Bevacizumab Paclitaxel Tolinapant	treatment	1 / 2	not_yet_recruiting
NCT05920798	A Study of FRaDCs for Ovarian Cancer	Folic acid Pembrolizumab	treatment	1 / 2	recruiting
NCT03348631	Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer	Tazemetostat	treatment	2	active_not_recruiting
NCT05026606	Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Etigilimab Nivolumab	treatment	2	active_not_recruiting